Premium
Treatment of fungal infections in HIV seropositive patients
Author(s) -
Gazzard B.G.
Publication year - 1992
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.1992.tb00681.x
Subject(s) - medicine , seborrhoeic dermatitis , ketoconazole , immunology , itraconazole , fluconazole , human immunodeficiency virus (hiv) , dermatology , immune system , seborrheic dermatitis , buccal administration , antifungal , pharmacology
A significant minority of HIV‐positive patients presents with fungal infections. Such infections become increasingly common in the terminal stage of the disease. It is unclear why HIV‐positive individuals should be particularly susceptible to fungal infections. Several immune abnormalities, both humoral and cellular, may be involved. Other factors, including other skin conditions and their treatment, also may increase susceptibility. There is some evidence, in HIV‐positive patients, of autoimmunity and of abnormal reactions to fungal infection. These include seborrhoeic dermatitis, dermatophytoses, follicular dermatitis and candidosis. Buccal and oesophageal candidosis respond well to itraconazole, ketoconazole and fluconazole but rapidly relapse. Prophylaxis probably is not indicated, however, since symptomatic treatment quickly takes effect.